-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dimesna in Lung Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dimesna in Lung Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dimesna in Lung Adenocarcinoma Drug Details: Dimesna (BNP7787) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dimesna in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Dimesna in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dimesna in Non-Small Cell Lung Cancer Drug Details: Dimesna (BNP7787)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-284 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-284 in Diffuse Large B-Cell Lymphoma Drug Details: LP-284...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-284 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-284 in Solid Tumor Drug Details: LP-284 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-284 in Mantle Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in Mantle Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-284 in Mantle Cell Lymphoma Drug Details: LP-284 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-284 in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-284 in B-Cell Non-Hodgkin Lymphoma Drug Details: LP-284 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-284 in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-284 in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LP-284 in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LP-284 in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LP-284 in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
Ewing Sarcoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Ewing Sarcoma - Drugs In Development, 2023’, provides an overview of the Ewing Sarcoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ewing Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Lung Adenocarcinoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Lung Adenocarcinoma - Drugs In Development, 2023’, provides an overview of the Lung Adenocarcinoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Lung Adenocarcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...